Pharmaceutical companies develop, manufacture, and market the drugs that treat disease and extend life — one of the most research-intensive and regulated industries in the global economy. Eli Lilly and Novo Nordisk have seen explosive growth driven by their GLP-1 weight loss and diabetes drugs, while AbbVie's immunology franchise anchored by Humira generates billions in annual revenue. Merck, AstraZeneca, and Gilead Sciences each maintain diverse oncology and specialty drug pipelines that drive long-term earnings visibility.
1
4.8
Eli Lilly
LLY
$1,040.00
+0.17%
P/E: 54.7
Eli Lilly is a dominant pharmaceutical stock riding the unprecedented commercial success of its GLP-1 therapies Mounjaro and Zepbound, which have positioned the company at the forefront of the obesity treatment revolution and made it one of the most highly valued pharma companies in history.
2
4.6
Merck
MRK
$121.41
+1.82%
P/E: 14.9
Merck is one of the world's most important pharmaceutical stocks, anchored by Keytruda—the best-selling cancer drug globally—with a deep pipeline in oncology, vaccines, and cardiometabolic disease.
3
4.6
Vertex Pharmaceuticals
VRTX
$491.47
+5.69%
P/E: 35.0
Vertex is the dominant pharmaceutical company in cystic fibrosis treatment, with its Trikafta franchise representing the standard of care and generating billions in highly profitable revenue with limited direct competition.
4
4.5
Novo Nordisk
NVO
$49.57
+1.31%
P/E: 2.9
Novo Nordisk is a pharmaceutical stock powerhouse and the undisputed global leader in GLP-1 therapies, with Ozempic and Wegovy generating explosive revenue growth that has made it Europe's most valuable company and a must-watch holding for pharmaceutical sector investors.
5
4.5
AbbVie
ABBV
$231.50
+1.76%
P/E: 25.3
AbbVie is a leading pharmaceutical stock with blockbuster immunology drugs Skyrizi and Rinvoq replacing Humira revenue, alongside strong franchises in oncology, aesthetics, and neuroscience.
6
4.4
AstraZeneca
AZN
$205.55
+0.50%
P/E: 34.6
AstraZeneca is a global pharmaceutical leader with a strong pipeline in oncology, cardiovascular, and respiratory therapies, consistently delivering above-industry revenue growth.
7
4.4
Gilead Sciences
GILD
$154.98
+2.09%
P/E: 17.8
Gilead Sciences is a major pharmaceutical company with a dominant franchise in HIV treatment and prevention, generating billions in annual revenue from its market-leading antiretroviral therapies including Biktarvy.
8
3.9
Bristol-Myers Squibb
BMY
$60.74
+1.47%
P/E: 28.7
Bristol-Myers Squibb is a top-tier global pharmaceutical company with a diverse portfolio of blockbuster drugs spanning oncology, cardiovascular, immunology, and fibrosis, generating tens of billions in annual revenue.
9
3.8
Pfizer
PFE
$27.58
+0.40%
P/E: 8.5
Pfizer is a major pharmaceutical stock undergoing a strategic transformation, pivoting from its COVID-19 windfall toward becoming an oncology leader through the Seagen acquisition, while offering investors an attractive dividend yield and a deeply discounted valuation relative to its large-cap pharm
10
3.2
Viatris
VTRS
Viatris is a global healthcare company formed from the Pfizer-Mylan merger, producing a broad portfolio of generic drugs, branded medicines, and biosimilars across diverse therapeutic areas.
11
2.6
Bayer AG
BAYRY
Bayer is a German life sciences giant with major positions in crop science, pharmaceuticals, and consumer health, though ongoing Monsanto-related litigation remains a key investor concern.
Latest from Otrai
Every trader has a strategy that looks great in their head. Backtesting is how you find out whether it actually works. Here is how to test strategies properly, what metrics matter, and why most backtest results are too good to be true.
A risk-reward ratio compares how much you stand to lose on a trade to how much you stand to gain. It is arguably the most important number in your trading plan, because it determines whether your strategy can survive a normal losing streak.
Every month, a handful of economic data releases move the forex market more in five minutes than most sessions move in five days. Non-Farm Payrolls, CPI prints, and central bank rate decisions create violent spikes, whipsaws, and trend shifts that can make or break a trading account.
A CFD is a contract between you and your broker to exchange the difference in an asset's price from when you open the trade to when you close it. You never own the underlying asset. That single distinction shapes everything about how CFDs work, what they cost, and why regulators treat them differently from traditional investing.